The CGM, which utilizes a single sensor for up to 14 days and doesn’t require a prescription, retails for $49 on the popular online marketplace. It also has eligibility on Amazon Prime, where available.
Lingo, an over-the-counter CGM system, was one of several highlights to come out of Abbott’s Diabetes business in 2024. Within two weeks of Dexcom launching Stelo, the first available OTC sensor, Abbott brought its own OTC glucose biosensor in Lingo to the market.
Dexcom CEO Kevin Sayer told Drug Delivery Business News last month that the company expects to make Stelo available on Amazon by the end of the first quarter.
Abbott received FDA clearance for Lingo and its Libre Rio over-the-counter (OTC) CGMs in June. Abbott Diabetes SVP of Commercial Operations Chris Scoggins explained the benefits of OTC CGMs last year.
Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre CGM technology platform. The consumer biowearable is available for consumers 18 years and older not on insulin. It tracks glucose in real time and provides personal insights and coaching. Abbott designed it to help people build healthy habits, retain their metabolism and improve their overall wellbeing.
Analysts said after Abbott’s latest quarterly earnings report that they expect continued growth from products like Lingo.
In a post on LinkedIn, Abbott’s official Lingo account wrote: “The future of nutrition just landed on Amazon. Lingo is now LIVE on Amazon. See how your body responds to food and exercise through glucose tracking with our 2-week plan. What you learn may surprise you. Get it in as little as 2 days with Prime. Add to cart and buy now!”
